197007-87-7

Basic information

• Product Name: (4-Bromopyridin-3-yl)methanol
• Synonyms: (4-Bromopyridin-3-yl)methanol;4-Bromo-3-pyridinemethanol;(4-broMopyridin-3-yl)Methanol hydrochloride;(4-Bromo-3-pyridyl)methanol hydrochloride;(4-Bromo-3-pyridyl)methanol
• CAS NO: 197007-87-7
• Molecular Formula: C₆H₆BrNO
• Molecular Weight: 188.02194
• Product Categories: pharmacetical
• Mol File: 197007-87-7.mol

Chemical Properties

• Boiling Point: 302.8 °C at 760 mmHg
• Flash Point: 136.9 °C
• Appearance: /
• Density: 1.668
• Vapor Pressure: 0.000427mmHg at 25°C
• Refractive Index: 1.598
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 12.96±0.10(Predicted)
• CAS DataBase Reference: (4-Bromopyridin-3-yl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (4-Bromopyridin-3-yl)methanol(197007-87-7)
• EPA Substance Registry System: (4-Bromopyridin-3-yl)methanol(197007-87-7)

Safety Data

• Statements: 41
• Safety Statements: 26-39
• Hazardous Substances Data: 197007-87-7(Hazardous Substances Data)

Usage

Uses

(4-Bromopyridin-3-yl)methanol is a useful synthesis reagent.

InChI:InChI=1/C6H6BrNO/c7-6-1-2-8-3-5(6)4-9/h1-3,9H,4H2

Upstream product

• 1150271-34-3 4-bromopyridine-3-carbaldehyde hydrobromide 
• 19524-06-2 4-bromopyridine hydrochloride 
• 154105-64-3 4-bromonicotinaldehyde 

Downstream Products

• 216012-93-0 5-Benzyloxy-1-(4-bromopyridin-3-ylmethyl)-3-(4-methylthiazol-2-yl)-1H-pyridin-2-one 
• 1053265-83-0 3-(Chloromethyl)-4-(4-chlorophenyl)pyridine 
• 1616102-18-1 4-((4-(tert-butyl)phenyl)ethynyl)nicotinaldehyde 
• 1616102-13-6 (4-((4-(tert-butyl)phenyl)ethynyl)pyridin-3-yl)methanol 
• 1616102-14-7 4-((4-tert-butylphenyl)ethynyl)-3-(methoxymethyl)pyridine 
• 1037830-79-7 4-bromo-3-(2-iodo-phenoxymethyl)-pyridine 
• 197007-88-8 4-bromo-3-pyridinemethanol benzyl ether 

Relevant articles and documents

SPIRO AROMATIC RING COMPOUND AND APPLICATION THEREOF

Provided is a compound of formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substituent, polymorph, prodrug, or metabolite thereof. Also provided is a method for preparing the compound of formula I. The compound of formula I has higher inhibitory activity against SHP2, and thus can be used to prevent or treat a disease related to SHP2.

An intra/intermolecular suzuki sequence to benzopyridyloxepines containing geometrically pure exocyclic tetrasubstituted alkenes

(Chemical Equation Presented) A route to enable the preparation of 5-benzylidenyl-benzopyridyloxepine analogues was developed to continue our research in the field of nuclear hormone receptor modulators. The key steps are1) a syn-stereoselective diboratio

Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them

Compounds of formula (I): wherein A represents a 5, 6 or 7-membered (hetero)aromatic or non-aromatic ring,n and n′ represent 0, 1 or 2X represents an alkylene chain as defined in the description,R3 represents an aryl or heteroaryl group,one of the groups R1 and R2 represents a hydrogen atom and the other represents a group of formula (II) as defined in the description. Medicinal products containing the same which are useful in treating conditions involving a defect in apoptosis.

NOVEL QUINOLINE DERIVATIVES AS POTASSIUM ION CHANNEL OPENERS

ABSTRACT The present invention is directed to novel quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to ion channels such as potassium channels.

NOVEL PYRIDINE DERIVATIVES AS POTASSIUM ION CHANNEL OPENERS

The present invention is directed to novel pyridine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to ion channels such as potassium channels.

trans-2,6-, 3,6- And 4,6-diaza-5,6,6a,7,8,12b-hexahydrobenzophenanthrene-10,11-diols as dopamine agonists

The title compounds were synthesized by replacing the thiophene moiety of A-86929(2a) with variously substituted pyridines. Dopamine D-1 and D-2 binding and adenylate cyclase assays indicate that 4,6-diaza compounds 15 are potent and selective full D1 agonists when R1 is H or a small substituent and R2=H, with D1 binding affinity and adenylate cyclase functional potency equivalent to that of A-86929(2a).